TCM
NVCR icon

Tuttle Capital Management’s NovoCure NVCR Stock Holding History

Tuttle Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-33,926
Closed -$3.08M – 205
2019
Q3 		$3.08M Buy
+33,926
New +$2.71M 0.82% 29

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Tuttle Capital Management's NVCR Position: Q4 2019 in Review

Tuttle Capital Management sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 33,926 shares — an estimated $3.08M sold.

Tuttle Capital Management first reported a position in NVCR in Q3 2019 and held it in 1 quarter. The position peaked at $3.08M in Q3 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

  • Tuttle Capital Management reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
  • Tuttle Capital Management sold 33,926 NovoCure shares in Q4 2019, an estimated $3.08M.
  • Tuttle Capital Management first reported a position in NovoCure in Q3 2019 and held it in 1 quarter.
  • Tuttle Capital Management's NovoCure position peaked at $3.08M in Q3 2019.
  • 262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Tuttle Capital Management's 13F filing for Q4 2019, filed 13 Jan 2020.